The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

Pattern Recognition Key to Fibrosing Lung Disease Diagnosis

January 19, 2016 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In October 2015, the FDA approved nintedanib. Developed as a cancer drug, nintedanib targets multiple tyrosine kinases. Based on phase 2 data that suggested its benefit in reducing declining lung function and acute exacerbations in patients with IP, two phase 3 randomized trials (INPULSIS-1 and INPULSIS-2) were conducted to assess the efficacy and safety of nintedanib (150 mg, twice daily) in patients with IFP.3

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
Explore This Issue
January 2016
Also By This Author
  • Management of Adults with JIA: Uveitis, MAS & More

Results of the studies showed a significant reduction in declining lung function in patients treated with nintedanib compared with placebo, with one study (INPULSIS-2) also showing a significant benefit in time to first acute exacerbation with nintedanib, whereas the other study (INPULSIS-1) found no significant difference between the two groups.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Results of the trials show that both drugs are safe, according to Dr. Noble, but also carry tolerability issues that are important and significant.

Dr. Distler

Dr. Distler

“Hope is on the horizon for the treatment of fibrotic disease,” said Oliver Distler, MD, Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, who moderated the session. The potential of these therapies to treat rheumatologic diseases is also under investigation with trials currently underway testing them in systemic sclerosis (SSc) ILD. “Nintedanib is [being tested] in a large placebo-controlled randomized clinical trial that just launched, and pirfenidone in a proof-of-concept open-label study,” he said, saying that the latter study was presented at the ACR meeting but was difficult to interpret for efficacy as it was not a controlled trial.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Noble ended his talk with a look to the future, citing three “exciting” phase II trials examining the association of IPF pathogenesis to potential therapies. The drugs being tested in these trials are Beta6 Integrin, LOXL2 and LPA receptor, all of which represent select, targeted, therapeutic approaches to IPF treatment. He said that future trials will address whether fibrosis can be reversed by targeted therapy before progression to end-stage disease.

Second Chance

If you missed this session, it’s not too late. Catch it on SessionSelect


Mary Beth Nierengarten is a writer, editor and journalist with more than 20 years of experience writing about clinical medicine and health-related issues, and lives in Minneapolis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomized trials. Lancet. 2011;377:1760–1669.
  2. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;29:370:2083–2092.
  3. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: AC&R, American College of Rheumatology, conference, Diagnosis, fibrosing lung disease, pattern recognition, Research, rheumatologyIssue: January 2016

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Lung Fibrosis
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)